In September 2010, the HMO Research Network (HMORN) received a 1-year administrative supplement to initiate development of a collaborative population-based laboratory, or “Collaboratory”. This award stems from NIH’s interest in enhancing the nation’s capacity to perform larger and more efficient epidemiological studies, interventions and analyses that collectively enable rapid responses to important questions in healthcare. The supplement is geared toward understanding the HMORN’s organizational structure and capacity in three areas: governance and operations; overall research portfolio and potential gaps in capacity; and data resources. This poster presents preliminary snapshots from the overall research portfolio of the HMORN for  Between November 2010 and January 2011, Collaboratory teams across the 15 HMORN sites in the U.S. queried local databases for research projects active at any time between 2008 and 2009 on which: (a) they were the prime site, and (b) 1 or more HMORN sites was a subcontract  This list of HMORN projects was supplemented with: (a) multi-site projects with no HMORN prime site (e.g., VSD, external PI) (b) sub-studies of the CERT and DEcIDE networks  Various administrative data sources were used to gather details about each study identified, including: (a) project title (e) prime and participating sites (b) PI (f ) start and end dates (c) total award (g) study design (d) funding agency (h) type of data collected  Flags were added to projects linked to HMORN consortia (e.g., CRN, CVRN, etc.), and those funded through ARRA mechanisms. The HMO Research Network – Portfolio Snapshots BACKGROUND METHODS WHO FUNDED HMORN ACTIVITIES 95% of the Network’s research funding came from federal sources. Non-federal sources include foundations and societies, pharmaceutical industry entities, and internal research funded by the health plans. HHS FUNDING – A CLOSER LOOK Funding from federal sources is shown below for 2008 and 2009 (approximate). Support for the HMORN’s largest consortia (cancer, cardiovascular health, vaccine safety, mental health, medication safety) is clearly evident – as well as the HMORN’s capacity for healthcare delivery research. HMORN PROJECT PARTICIPATION The total number of sites involved ranged from 2 to 15 per project. On average, 5 sites were involved, with a standard deviation of 3.2. Of the 119 HMORN studies reported, 45 (38%) included non-HMORN partners. A total of 42 different external partners were reported, most of which are University-based. LIMITATIONS Not all projects may have been captured and reported. A greater portion of Cancer Research Network (CRN) projects may be reported. When number of VSD sites was not known, 8 sites were assumed. ACKNOWLEDGEMENTS Special thanks to and Karin Johnson, PhD and Sarah McDonald of GHRI, the entire HMORN Collaboratory team, and the Cancer Research Network supplement U19 CA – S12. HMORN PROJECT LEADERSHIP Fifty-two different researchers from within the HMORN led or PI’ed a Network-based project during External partners led or PI’ed 15 HMORN projects (13%) during the same period. PROJECT TYPE The primary study design was reported for 110 of the projects. Of these, 62% primarily utilized observational methods. LEAD SITES The number of projects led per HMORN site ranged from 0 to 29. Of the 15 U.S. sites, 13 led an HMORN project during 2008 and 2009.